About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Gene Expression in Hyperparathyroidism | Clinical Trials | Clareo Health

Back to clinical trial search

TERMINATEDNCT03044600

Gene Expression in Hyperparathyroidism

Objectives: 1. To better define the differences in molecular genetics of parathyroid tumors in patients with MEN1, single gland parathyroid disease in patients less than 50 years old and single gland...

Lead sponsor: M.D. Anderson Cancer Center•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

M.D. Anderson Cancer Center

Patient charts will be reviewed to collect demographic data, pre-operative and post-operative clinical and laboratory data, operative reports, and pathology reports. Archived formalin-fixed paraffin-embedded (FFPE) tissue blocks from surgical specimens of patients will be stained for parafibromin to evaluate for HRPT2 mutations.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. All patients previously enrolled in parathyroid tissue banking under protocol Lab08-0034.
•2. For the subgroup designated for HRPT2 mutation testing:
•Patients with primary hyperparathyroidism who are younger than 50 years of age and have tested negative for MEN1, between January 1, 1980 and the present.

Exclusion Criteria

•N/A

Related studies

RECRUITINGPhase 3

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

NCT07081997 · Hypoparathyroidism, Endocrine System Diseases, and more

RECRUITINGPhase 3

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

NCT03633708 · Secondary Hyperparathyroidism, Chronic Kidney Disease

Parathyroidectomy After Kidney Transplantation

NCT07415421 · Hyperparathyroidism, Kidney Transplantation Recipients

Parathyroidectomy and Mobility Study

NCT07103876 · Hyperparathyroidism, Parathyroid, and more

Dual-Channel Near-Infrared Autofluorescence Imaging and AI Analysis to Locate Parathyroid Glands (PTFinder)

NCT07010380 · Thyroid Neoplasms, Hyperparathyroidism, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 23, 2019Terms

Trial snapshot

StatusTERMINATED

Phase—

Enrollment22

Start dateNov 2012

Last updatedMay 23, 2019

Condition

Parathyroid Disease Hyperparathyroidism

Locations shown

University of Texas MD Anderson Cancer Center

Houston, Texas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 23, 2019Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions